Similarly, Meng et al. (2020) have highlighted the potential of pan-JAK inhibitor jaktinib hydrochloride for treating COVID-19 patients, given the role of jaktinib in preventing JAK-dependent cytokine-induced immune activation and AAK1 and GAK-mediated viral entry and subsequent proliferation (Figure 3). This evidence concerns the gene AAK1 and COVID-19.